Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical failure (proportion of participants who were not cured or substantially improved (> 70% reduction in cough severity measure) at · children with subacute cough following acute bronchiolitis
The intervention showed no clear difference in clinical failure (proportion of participants who were not cured or… (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with same dose ICS (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · children with asthma
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with 1 or more exacerbations requiring oral corticosteroids… compared with daily ICS (low certainty).
1 finding from 1 review
Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Patients with at least 1 exacerbation requiring emergency department/acute care visit (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with at least 1 exacerbation requiring emergency… compared with daily ICS (low certainty).
1 finding from 1 review
Change from baseline AM PEFR (%) (duration 44 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Asthma control · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in proportion of asthma control days over the period (duration 44 to 52… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change from baseline mean daily use of β2‐agonists (puffs/day) (duration 24 to 44 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change in height · Children and adults with persistent asthma.
Intermittent 'as needed' ICS probably leads to higher change in height (cm) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Leaving the study early · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in overall withdrawals (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review